title: Pazopanib versus sunitinib in metastatic renal-cell carcinoma.
abstract: BACKGROUND
  Pazopanib and sunitinib provided a progression-free survival benefit, as compared with placebo or interferon, in previous phase 3 studies involving patients with metastatic renal-cell carcinoma. This phase 3, randomized trial compared the efficacy and safety of pazopanib and sunitinib as first-line therapy.
  
  
  METHODS
  We randomly assigned 1110 patients with clear-cell, metastatic renal-cell carcinoma, in a 1:1 ratio, to receive a continuous dose of pazopanib (800 mg once daily; 557 patients) or sunitinib in 6-week cycles (50 mg once daily for 4 weeks, followed by 2 weeks without treatment; 553 patients). The primary end point was progression-free survival as assessed by independent review, and the study was powered to show the noninferiority of pazopanib versus sunitinib. Secondary end points included overall survival, safety, and quality of life.
  
  
  RESULTS
  Pazopanib was noninferior to sunitinib with respect to progression-free survival (hazard ratio for progression of disease or death from any cause, 1.05; 95% confidence interval [CI], 0.90 to 1.22), meeting the predefined noninferiority margin (upper bound of the 95% confidence interval, <1.25). Overall survival was similar (hazard ratio for death with pazopanib, 0.91; 95% CI, 0.76 to 1.08). Patients treated with sunitinib, as compared with those treated with pazopanib, had a higher incidence of fatigue (63% vs. 55%), the hand-foot syndrome (50% vs. 29%), and thrombocytopenia (78% vs. 41%); patients treated with pazopanib had a higher incidence of increased levels of alanine aminotransferase (60%, vs. 43% with sunitinib). The mean change from baseline in 11 of 14 health-related quality-of-life domains, particularly those related to fatigue or soreness in the mouth, throat, hands, or feet, during the first 6 months of treatment favored pazopanib (P<0.05 for all 11 comparisons).
  
  
  CONCLUSIONS
  Pazopanib and sunitinib have similar efficacy, but the safety and quality-of-life profiles favor pazopanib. (Funded by GlaxoSmithKline Pharmaceuticals; COMPARZ ClinicalTrials.gov number, NCT00720941.).
authors: Department of Medicine, Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021, USA. motzerr@mskcc.org
authors: Robert J
authors: RJ
authors: Motzer
authors: Thomas E
authors: TE
authors: Hutson
authors: David
authors: D
authors: Cella
authors: James
authors: J
authors: Reeves
authors: Robert
authors: R
authors: Hawkins
authors: Jun
authors: J
authors: Guo
authors: Paul
authors: P
authors: Nathan
authors: Michael
authors: M
authors: Staehler
authors: Paul
authors: P
authors: de Souza
authors: Jaime R
authors: JR
authors: Merchan
authors: Ekaterini
authors: E
authors: Boleti
authors: Kate
authors: K
authors: Fife
authors: Jie
authors: J
authors: Jin
authors: Robert
authors: R
authors: Jones
authors: Hirotsugu
authors: H
authors: Uemura
authors: Ugo
authors: U
authors: De Giorgi
authors: Ulrika
authors: U
authors: Harmenberg
authors: Jinwan
authors: J
authors: Wang
authors: Cora N
authors: CN
authors: Sternberg
authors: Keith
authors: K
authors: Deen
authors: Lauren
authors: L
authors: McCann
authors: Michelle D
authors: MD
authors: Hackshaw
authors: Rocco
authors: R
authors: Crescenzo
authors: Lini N
authors: LN
authors: Pandite
authors: Toni K
authors: TK
authors: Choueiri
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary; D018572:Disease-Free Survival; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007191:Indazoles; D007211:Indoles / Q000009:adverse effects / Q000627:therapeutic use*; D053208:Kaplan-Meier Estimate; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D011743:Pyrimidines / Q000009:adverse effects / Q000627:therapeutic use*; D011758:Pyrroles / Q000009:adverse effects / Q000627:therapeutic use*; D011788:Quality of Life; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use*; D000077210:Sunitinib
chemical_list: D020533:Angiogenesis Inhibitors; D007191:Indazoles; D007211:Indoles; D011743:Pyrimidines; D011758:Pyrroles; D013449:Sulfonamides; C516667:pazopanib; D000077210:Sunitinib